glp 1 agonist in ckd GLP1 Receptor Agonists vs SGLT2-I Preventing in T2DM: An Interview – AJKD Blog GLP-1 RAs, Other Agents, Underused
Description
Diabetes Care 48 (7), 10571082
Zhang X, Belousoff MJ, Zhao P, et al
IRE1XBP1 signaling in leukocytes controls prostaglandin biosynthesis and pain
Effects on Obesity Obesity, as a chronic recurrent disease, is known to increase the risk of developing T2MD, hypertension, dyslipidemias, CVDs, NAFLD, and other diseases, leading to a poor quality of life and increased mortality (167)
These medications were initially created to treat type 2 diabetes and have been extensively researched for several decades
